@BroadInstitute a shift from Permanently editing DNA to Temporarily revising RNA – An approach with promise for addressing the risk of developing Alzheimer’s by deactivating APOE4 – RESCUE: RNA Editing for Specific C to U Exchange, the platform builds on REPAIR: RNA Editing for Programmable A to I | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« FIVE Forthcoming Books on CRISPR in 2019-2020: Flooded market or CRISPR-fatigued readers – Not to Worry !!!!!

Engineered Bacteria used as Trojan Horse for Cancer Immunotherapy »

@BroadInstitute a shift from Permanently editing DNA to Temporarily revising RNA – An approach with promise for addressing the risk of developing Alzheimer’s by deactivating APOE4 – RESCUE: RNA Editing for Specific C to U Exchange, the platform builds on REPAIR: RNA Editing for Programmable A to I

July 12, 2019 by 2012pharmaceutical

@BroadInstitute a shift from Permanently editing DNA to Temporarily revising RNA – An approach with promise for addressing the risk of developing Alzheimer’s by deactivating APOE4 – RESCUE: RNA Editing for Specific C to U Exchange, the platform builds on REPAIR: RNA Editing for Programmable A to I

Reporter: Aviva Lev-Ari, PhD, RN

2.1.3.14

2.1.3.14 @BroadInstitute a shift from Permanently editing DNA to Temporarily revising RNA – An approach with promise for addressing the risk of developing Alzheimer’s by deactivating APOE4 – RESCUE: RNA Editing for Specific C to U Exchange, the platform builds on REPAIR: RNA Editing for Programmable A to I, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

The RNA editors converted “the nucleotide base adenine to inosine, or letters A to I. Zhang and colleagues took the REPAIR fusion and evolved it in the lab until it could change cytosine to uridine, or C to U.”
Using Cas13, Zhang’s team was able to take the APOE4 gene — believed to carry the added risk of spurring Alzheimer’s — and changed it to a benign APOE2.

RNA-guided DNA insertion with CRISPR-associated transposases

Jonathan Strecker ¹,²,³,⁴,
Alim Ladha¹,²,³,⁴,
Zachary Gardner¹,²,³,⁴,
Jonathan L. Schmid-Burgk¹,²,³,⁴,
Kira S. Makarova⁵,
Eugene V. Koonin⁵,
Feng Zhang ¹,²,³,⁴,*

¹Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
²McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
³Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
⁴Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
⁵National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA.